Literature DB >> 19530897

Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis.

Guilherme Carneiro1, Delia C M Santos, Monica C Oliveira, Ana P Fernandes, Luciana S Ferreira, Gilson A Ramaldes, Elziria A Nunan, Lucas A M Ferreira.   

Abstract

The present study aimed to evaluate the potential of liposomes loaded with paromomycin (PA), an aminoglycoside antibiotic associated with poor skin penetration, for the topical treatment of cutaneous leishmaniasis (CL). Fluid liposomes were prepared and characterized for particle size, zeta potential, and drug entrapment. Permeation studies were performed with two in vitro models: intact and stripped skin. The antileishmanial activity of free and liposomal PA was evaluated in BALB/c mice infected by Leishmania (L.) major. Drug entrapment ranged from 10 to 14%, and the type of vesicle had little influence on this parameter. Particle size and polydispersity index of the vesicles composed by phosphatidylcholine (PC) and PC/cholesterol (Chol) ranged from of 516 to 362 nm and 0.7 to 0.4, respectively. PA permeation across intact skin was low, regardless of the formulation tested, while drug penetration into skin (percent of the applied dose) from PC (7.2 +/- 0.2%) and PC/Chol (4.8 +/- 0.2%) liposomes was higher than solution (1.9 +/- 0.1%). PA-loaded liposomes enhanced in vitro drug permeation across stripped skin and improved the in vivo antileishmanial activity in experimentally infected mice. Our findings suggest that the liposomes represent a promising alternative for the topical treatment of CL using PA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19530897     DOI: 10.3109/08982100903015025

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  6 in total

1.  Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

Authors:  Antara Banerjee; Manjarika De; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

2.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

Review 3.  Liposomal drug delivery systems for the treatment of leishmaniasis.

Authors:  Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato
Journal:  Parasitol Res       Date:  2022-09-16       Impact factor: 2.383

4.  Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis.

Authors:  Ma Florencia Peralta; Nadina A Usseglio; Ma Estefanía Bracamonte; Ma Laura Guzmán; Ma Eugenia Olivera; J Diego Marco; Paola A Barroso; Dolores C Carrer
Journal:  Drug Deliv Transl Res       Date:  2021-01-27       Impact factor: 4.617

5.  Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB).

Authors:  Rebuma Firdessa; Liam Good; Maria Cecilia Amstalden; Kantaraja Chindera; Nor Fadhilah Kamaruzzaman; Martina Schultheis; Bianca Röger; Nina Hecht; Tobias A Oelschlaeger; Lorenz Meinel; Tessa Lühmann; Heidrun Moll
Journal:  PLoS Negl Trop Dis       Date:  2015-10-02

6.  Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis.

Authors:  Diana Berenguer; Lilian Sosa; Magdalena Alcover; Marcella Sessa; Lyda Halbaut; Carme Guillén; Roser Fisa; Ana Cristina Calpena-Campmany; Cristina Riera
Journal:  Pharmaceutics       Date:  2019-11-15       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.